Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: BRT develops therapeutic products using adult stem cells. Key programs include brtxDISC (BRTX-100 for lumbar disc disorders), the ThermoStem Program (brown adipose for metabolic disorders), and a biologics-based cosmetic business. The company is currently conducting a Phase 2 clinical trial for BRTX-100.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenues | $328,300 | $124,100 |
| Net Loss | $(7,996,062) | $(6,251,817) |
| Net Loss Per Share (Basic & Diluted) | $(0.94) | $(0.84) |
| Cash and Cash Equivalents (End of Period) | $1,555,251 | $2,252,247 |
| Marketable Securities | $5,825,685 | $10,184,701 |
| Working Capital | $3,926,572 | $7,395,815 |
| Warrant Liabilities | $2,580,379 | $2,520,851 |
| Accumulated Deficit | $(163,674,777) | $(152,951,151) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 164% year-over-year (YoY) to $328,300, driven primarily by a $300,000 increase in cosmetic product sales under a supply agreement with Cartessa Aesthetics. Royalty revenue decreased due to fewer disc procedures.
- Operating Expenses: Total operating expenses rose 26% to $8.43 million. Research and Development (R&D) expenses increased 38% to $4.87 million, largely due to $1.18 million in additional costs for the Phase 2 clinical trial. General and Administrative (G&A) expenses increased 12% to $3.56 million.
- Net Loss Expansion: Net loss widened by $1.74 million YoY. While operating losses increased, the company recognized a $59,528 loss on the change in fair value of warrant liabilities in 2025, compared to a $1.87 million loss in 2024. However, the 2024 period included a one-time $1.71 million gain on the exchange of warrants, which was absent in 2025.
- Liquidity Position: Cash and cash equivalents increased by $1.01 million during the period, supported by net proceeds of approximately $1.94 million from an At-The-Market (ATM) offering and $4.5 million from the net sale of marketable securities. However, total liquid assets (cash + securities) decreased by approximately $4.36 million compared to year-end 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management states that current funds are insufficient to complete development activities or attain profitability. The company anticipates continued net losses and negative cash flows, raising "substantial doubt" about its ability to continue as a going concern for at least twelve months without additional financing.
- Financing Activities: The company raised approximately $2.0 million in gross proceeds via its ATM offering during the six months ended June 30, 2025. On June 16, 2025, the Board authorized a $2.0 million common stock repurchase program, though no repurchases have occurred.
- Internal Control Weaknesses: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2025. Material weaknesses persist regarding adherence to formal policies, risk assessment, and accounting for warrant liabilities. Management is engaging external consultants to remediate these issues.
- Tax Legislation: The company is evaluating the impact of the "Tax Reform Act of 2025" signed into law on July 4, 2025, which includes changes to bonus depreciation and R&D expensing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $7.38 million in total liquid assets (cash + marketable securities) against the $5.5 million cash burn rate from operations in the first half of 2025.
- Revenue Concentration: Confirm the stability of the single customer relationships for both product sales (Cartessa) and royalty revenue (SCTC), as all revenue is derived from one customer per category.
- Internal Controls: Monitor progress on remediation of material weaknesses in financial reporting, specifically regarding warrant accounting and journal entry controls.
- Clinical Trial Costs: Track the burn rate associated with the Phase 2 clinical trial for BRTX-100, which drove a significant portion of the R&D expense increase.
- Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $2.58 million warrant liability, which creates non-cash volatility in the net loss.